This article focuses on the business state of Constellation Pharmaceuticals, an epigenetics firm based in Cambridge, Massachusetts. It discusses the company's series financing in the summer of 2010, the U.S. Food and Drug Administration (FDA) approval won by the company's histone methylases and demethylases, and the plan of the company to develop drugs targeting a range of histone methylation enzymes.